MX2023002816A - Sal de un compuesto para degradar btk, forma cristalina de este y uso de estos en medicina. - Google Patents

Sal de un compuesto para degradar btk, forma cristalina de este y uso de estos en medicina.

Info

Publication number
MX2023002816A
MX2023002816A MX2023002816A MX2023002816A MX2023002816A MX 2023002816 A MX2023002816 A MX 2023002816A MX 2023002816 A MX2023002816 A MX 2023002816A MX 2023002816 A MX2023002816 A MX 2023002816A MX 2023002816 A MX2023002816 A MX 2023002816A
Authority
MX
Mexico
Prior art keywords
salt
compound
crystal form
medicine
acetate
Prior art date
Application number
MX2023002816A
Other languages
English (en)
Inventor
Pangke Yan
Yao Li
Chen Zhang
Longbin Huang
Jianmin Wang
Yuting Liao
Guozhi Zhu
Original Assignee
Haisco Pharmaceuticals Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haisco Pharmaceuticals Pte Ltd filed Critical Haisco Pharmaceuticals Pte Ltd
Publication of MX2023002816A publication Critical patent/MX2023002816A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/06—Oxalic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/10—Polyhydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
    • C07C65/10—Salicylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proporciona una sal de un compuesto para degradar BTK y/o una forma cristalina, preparación de estos y una aplicación de estos; la sal farmacéutica del compuesto como se muestra en la fórmula (I) y la forma cristalina, donde la sal farmacéutica se selecciona entre maleato, fumarato, sal de ácido halógeno (preferentemente bromhídrico y clorhídrico), sulfato, fosfato, L-tartrato, citrato, L-malato, hipurato, D-glucuronato, glicolato, mucato, succinato, lactato, orotato, pamoato, glicinato, sal de alanina, sal de arginina, cinamato, benzoato, bencenosulfonato, p-toluenosulfonato, acetato, propionato, valerianato, trifenilacetato, sal de L-prolina, ferulato, 2-hidroxietanosulfonato, mandelato, nitrato, mesilato, malonato, gentisato, salicilato, oxalato o gluturato; (ver Fórmula).
MX2023002816A 2020-09-09 2021-09-08 Sal de un compuesto para degradar btk, forma cristalina de este y uso de estos en medicina. MX2023002816A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010933538 2020-09-09
CN202110869600 2021-08-03
PCT/CN2021/117174 WO2022052950A1 (zh) 2020-09-09 2021-09-08 一种降解btk化合物的盐及其晶型和在医药上的用途

Publications (1)

Publication Number Publication Date
MX2023002816A true MX2023002816A (es) 2023-03-17

Family

ID=80632092

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002816A MX2023002816A (es) 2020-09-09 2021-09-08 Sal de un compuesto para degradar btk, forma cristalina de este y uso de estos en medicina.

Country Status (11)

Country Link
US (1) US20240018147A1 (es)
EP (1) EP4212534A1 (es)
JP (1) JP2023541140A (es)
KR (1) KR20230091088A (es)
CN (1) CN116528870A (es)
AU (1) AU2021341998A1 (es)
CA (1) CA3192125A1 (es)
IL (1) IL301156A (es)
MX (1) MX2023002816A (es)
TW (1) TW202220997A (es)
WO (1) WO2022052950A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017197056A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
CN109422752B (zh) * 2017-09-03 2023-04-07 上海美志医药科技有限公司 一类具有抑制并降解布鲁顿酪氨酸蛋白激酶Btk活性的化合物
WO2019127008A1 (zh) * 2017-12-26 2019-07-04 清华大学 一种靶向降解btk的化合物及其应用
US20200121684A1 (en) * 2018-03-10 2020-04-23 Yale University Modulators of btk proteolysis and methods of use
KR20220016049A (ko) * 2019-05-31 2022-02-08 스촨 하이스코 파마수티컬 씨오., 엘티디 Btk 억제제 고리 유도체, 이의 제조 방법 및 이의 약제학적 응용
CN110724143B (zh) * 2019-10-09 2021-03-23 清华大学 一种靶向btk蛋白降解化合物的制备及其在治疗自身免疫系统疾病与肿瘤中的应用

Also Published As

Publication number Publication date
IL301156A (en) 2023-05-01
US20240018147A1 (en) 2024-01-18
JP2023541140A (ja) 2023-09-28
EP4212534A1 (en) 2023-07-19
WO2022052950A1 (zh) 2022-03-17
TW202220997A (zh) 2022-06-01
CN116528870A (zh) 2023-08-01
CA3192125A1 (en) 2022-03-17
AU2021341998A1 (en) 2023-05-25
KR20230091088A (ko) 2023-06-22

Similar Documents

Publication Publication Date Title
US9814714B2 (en) Kinase modulation, and indications therefor
TWI670088B (zh) 含有阿申那平（ａｓｅｎａｐｉｎｅ）之貼附劑之製造方法
AU2015305214A1 (en) Compositions and uses of amidine derivatives
CN1571664A (zh) 经皮吸收型制剂
CN114667147A (zh) 用四氢萘衍生物作为雌激素受体降解剂的治疗乳腺癌的方法
WO2013078608A1 (en) Donepezil pamoate and methods of making and using the same
EP1731147A1 (en) External preparation
US20180250278A1 (en) Donepezil derivative and use thereof
US20210353621A1 (en) Methods of treating prostate cancer
EP4279138A3 (en) Crystal of compound as c-met kinase inhibitor and preparation method therefor and use thereof
MX2023002816A (es) Sal de un compuesto para degradar btk, forma cristalina de este y uso de estos en medicina.
CN114072144A (zh) 外用磷酸肌醇3-激酶抑制剂
JP4579920B2 (ja) アトルバスタチン外用剤組成物
US20190000847A1 (en) Therapeutic agent for a wound
AU2017227280A1 (en) Liquid medicinal preparation
CN104860882A (zh) 一种治疗高血脂症的药物匹伐他汀钙组合物
JP2014521738A (ja) コロールおよびスタチンの併用
AU2019283825A1 (en) Crystalline form of 1 ,3-thiazol-5-ylmethyl [(2r,5r)-5-{[(2s)-2-[(methyl{[2-(propan-2-yl)-1 ,3-thiazol-4-yl]methyl}carbamoyl)amino] -4-(morpholin-4-yl)butanoyl 9amino}-1 ,6-diphenylhexan-2-yl]carbamate or cobicistat
WO2014096176A1 (en) Novel crystalline forms of ceftaroline fosamil
US9155715B2 (en) Transdermal composition comprising tolterodine
WO2019224780A1 (en) Treatments
JP6611932B2 (ja) 医薬組成物
CN104844506A (zh) 一种治疗高血脂症的药物匹伐他汀钙化合物
US20220213021A1 (en) Compositions of biologically active menaquinol derivatives and methods of treatment
US20070043078A1 (en) Angiogenesis inhibitor